Published March 21, 2013
Laurent Levy, CEO and co-founder of Nanobiotix, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, will speak at UB at 6:30 p.m. March 26 in 109 Knox Hall, North Campus.
The lecture is co-sponsored by the Entrepreneurship Academy of the Undergraduate Academies and the Office of Science, Technology Transfer and Economic Outreach.
In his talk, titled “From my Bathroom to the Stock Market,” Levy will discuss Nanobiotix, in particular the story behind the company: “What we have done well, what we have done wrong, what were the unexpected levers, the fun…”
NanoXray, Nanobiotix’s first-in-class, proprietary technology, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy and brachytherapy treatments, and are applicable to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product, NBTXR3, based on NanoXray, is under clinical development for soft tissue sarcoma.
For more information, contact the Undergraduate Academies at 645-8177 or firstname.lastname@example.org.